| HOME >> MEDICINE >> TECHNOLOGY |
impairment----340--Other (income) expense, net(55)614749Income before income taxes2,2422,86312,05211,466Income tax expense1599974,1064,095Net income$2,083$1,866$7,946$7,371Income per common share:Basic$0.08$0.07$0.29$0.26Diluted$0.07$0.07$0.28$0.26Dividends declared per share$0.025$--$0.050$--Weighted-average common shares outstanding:Basic26,82027,46926,96727,441Diluted27,35727,74527,41127,759 CRYOLIFE, INC. AND SUBSIDIARIESFinancial Highlights(In thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,2012201120122011(Unaudited)(Audited)Preservation Services:Cardiac tissue
$
7,094$
6,629$
29,756$
26,618Vascular tissue8,1388,14633,84733,175Total preservation services15,23214,77563,60359,793Products:BioGlue and BioFoam13,35312,51953,21149,455PerClot1,0099173,0782,528HemoStase--(96)--1,699Revascularization technologies1,9852,4158,0925,705HeRO Graft1,106--3,115--Total products17,45315,45567,49659,387Other115167619446Total revenues$32,800$30,397$131,718$119,626Revenues:U.S.
$
25,771$
24,475$
103,804$
95,975International7,0295,92227,91423,651Total revenues$32,800$30,397$131,718$119,626 December 31,December 31,20122011(Audited)(Audited)Cash, cash equivalents, and restricted cash and securities
$
18,332$
27,017Total current assets77,50383,870Total assets157,156147,864Total current liabilities21,43021,457Total liabilities29,04426,326Shareholders' equity128,112121,538 CRYOLIFE, INC. AND SUBSIDIARIESUnaudited Reconciliation ofNon-GAAP Adjusted Net Income and Adjusted Income per Common Share – Diluted(In thousands, except per share data)Three Months EndedTwelve Months EndedDecember 31,December 31,2012201120122011GAAP:Income before income taxes$2,242$2,863$12,052$11,466Income tax expense1599974,1064,095Net in
'/>"/>
| SOURCE CryoLife, Inc. Copyright©2012 PR Newswire. All rights reserved |